Your browser is no longer supported. Please, upgrade your browser.
ATOS Atossa Therapeutics, Inc. daily Stock Chart
Atossa Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own0.57% Shs Outstand9.21M Perf Week-0.59%
Market Cap31.15M Forward P/E- EPS next Y-1.04 Insider Trans0.00% Shs Float9.18M Perf Month9.09%
Income-16.10M PEG- EPS next Q-0.28 Inst Own2.70% Short Float2.11% Perf Quarter118.18%
Sales- P/S- EPS this Y63.10% Inst Trans- Short Ratio0.21 Perf Half Y114.01%
Book/sh1.12 P/B3.00 EPS next Y18.80% ROA-104.80% Target Price- Perf Year58.49%
Cash/sh1.01 P/C3.31 EPS next 5Y- ROE-119.50% 52W Range0.75 - 4.27 Perf YTD114.01%
Dividend- P/FCF- EPS past 5Y53.30% ROI- 52W High-17.66% Beta2.62
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low365.67% ATR0.32
Employees2 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)55.19 Volatility7.67% 9.69%
OptionableYes Debt/Eq0.00 EPS Q/Q48.00% Profit Margin- Rel Volume0.29 Prev Close3.36
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume927.25K Price3.52
Recom2.00 SMA20-1.37% SMA5025.58% SMA20092.53% Volume232,552 Change4.64%
Jan-26-18Initiated Maxim Group Buy $2
Jul-08-20 09:30AM  
Jun-13-20 08:05AM  
Jun-11-20 09:30AM  
Jun-05-20 03:49PM  
May-29-20 08:00AM  
May-28-20 09:30AM  
May-20-20 09:30AM  
May-13-20 09:30AM  
May-07-20 09:30AM  
Apr-27-20 08:00AM  
Apr-22-20 03:40PM  
Apr-20-20 08:00AM  
Apr-17-20 10:51AM  
Apr-16-20 08:00AM  
Apr-02-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:30AM  
Mar-02-20 08:30AM  
Feb-05-20 08:00AM  
Feb-04-20 05:10PM  
Jan-22-20 08:30AM  
Jan-06-20 08:00AM  
Dec-19-19 08:30AM  
Dec-16-19 11:09AM  
Dec-05-19 08:30AM  
Nov-13-19 08:00AM  
Oct-23-19 08:30AM  
Oct-16-19 08:30AM  
Oct-15-19 08:30AM  
Sep-30-19 08:30AM  
Sep-06-19 08:30AM  
Sep-03-19 08:00AM  
Aug-13-19 01:26PM  
Jul-30-19 08:30AM  
Jul-17-19 08:30AM  
Jul-11-19 08:30AM  
Jun-28-19 11:38AM  
Jun-27-19 08:00AM  
Jun-19-19 03:56PM  
May-30-19 08:00AM  
May-13-19 05:21PM  
Apr-30-19 06:10AM  
Apr-25-19 12:00PM  
Apr-22-19 08:45AM  
Mar-28-19 04:30PM  
Mar-27-19 10:15AM  
Mar-26-19 08:30AM  
Mar-18-19 08:30AM  
Mar-14-19 01:01PM  
Feb-27-19 06:05AM  
Feb-07-19 08:30AM  
Feb-04-19 08:30AM  
Jan-30-19 09:15AM  
Jan-28-19 08:00AM  
Jan-10-19 07:00AM  
Jan-09-19 11:58AM  
Dec-28-18 07:20AM  
Dec-19-18 08:05AM  
Dec-07-18 12:07PM  
Dec-03-18 08:00AM  
Nov-21-18 08:05AM  
Nov-13-18 04:10PM  
Oct-25-18 09:10AM  
Oct-18-18 04:00PM  
Oct-11-18 08:00AM  
Sep-26-18 09:05AM  
Sep-25-18 08:20AM  
Sep-14-18 09:10AM  
Sep-13-18 08:00AM  
Sep-12-18 08:00AM  
Aug-23-18 09:02AM  
Aug-21-18 09:05AM  
Aug-13-18 04:15PM  
Aug-01-18 09:05AM  
Jul-31-18 08:15AM  
Jul-30-18 08:30AM  
Jul-25-18 09:05AM  
Jul-18-18 08:00AM  
Jul-13-18 08:00AM  
Jun-27-18 12:55PM  
Jun-26-18 08:00AM  
Jun-20-18 08:00AM  
Jun-14-18 08:00AM  
Jun-11-18 09:24PM  
May-31-18 09:05AM  
May-25-18 08:00AM  
May-24-18 01:32PM  
May-15-18 08:00AM  
May-14-18 04:24PM  
May-11-18 08:00AM  
May-08-18 08:00AM  
May-07-18 08:15AM  
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, conducting two Phase II studies, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is also developing intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. Its medical devices also include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator, which collect specimens of nipple aspirate fluid for cytological testing. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.